by adjuvant chemotherapy in the early stages, while chemotherapy (neoadjuvant) followed by interval debulking surgery in advanced dis ease with variations depending on the histo pathological grade and the general condition of the patient [1] .
Preoperative staging is done by imaging fol lowed by surgical staging at laparotomy. Imaging by ultrasonography or computed tomography (CT)/MRI is widely acceptable for carcinoma of the ovary. Over the past few years, especially the past decade, with the advent of functional imaging using PET with 18 Ffluorodeoxyglucose (FDG) imaging, diagnostic imaging in oncol ogy has undergone a paradigm shift. With the advent of the routine clinical use of FDGPET in the early nineties for staging and followup of various cancers, we have now arrived at the time of advanced molecular imaging using PET/CT, which combines both functional and ana tomical information. Based on the increas ing body of literature in the last few years, we now place PET/CT at a certain point in the management of ovarian carcinomas.
Ovarian cancer is the sixth most common cancer among women [1, 2] . Worldwide there are more than 200,000 new cases of ovarian cancer each year, accounting for around 4% of all cancers diagnosed in women [3] . A wom an's risk of developing cancer of the ovaries by the age of 75 years varies between countries, ranging from 0.5 to 1.6%, corresponding to an agestandardized rate of five to 14 cases per year in 100,000 women. In Europe, ovarian cancer is the leading cause of gynecological cancer death; just over a third of women are alive 5 years after diagnosis [4] , largely because most women with ovarian cancer present at an advanced stage when surgical cure is usually impossible [5] .
The International Federation of Obstetricians and Gynecologists (FIGO) staging is used to describe the spread of the disease (Box 1). Fewer than 30% of women present with stage I or II ovarian cancer [6] .
Management of carcinoma of the ovary involves evaluation and primary staging, fol lowed by primary debulking surgery followed
Review
Impact of FDGPET and PET/CT imaging in the clinical decisionmaking of ovarian carcinoma: an evidencebased approach The most definitive role of fluorodeoxyglucose (FDG)-PET/computed tomography (CT) at present is surveillance and detecting recurrence in patients who have completed primary therapy but demonstrate a rising serum tumor marker (e.g., CA-125 levels). In this scenario, PET/CT demonstrates high sensitivity and accuracy in detecting lesions that are otherwise challenging, and appears superior (with less interobserver variability) compared with CT alone. Despite the fact that peritoneal deposits may be missed by PET/CT, the overall performance is better than CT alone. FDG-PET does not play a significant additional role in the primary diagnosis of ovarian cancers; however, the role of combined PET/CT modality has recently begun to be re-explored for initial disease staging, particularly because PET/CT can pick up small unsuspected lesions and thereby provide a better disease assessment of the whole body in a single examination. The baseline PET/CT also subserves an important role for future monitoring of therapy response. Therapy monitoring by PET could help to optimize neoadjuvant therapy protocols and to avoid ineffective therapy in nonresponders early in its course, although PET/CT has cost-effectiveness issues that need further evaluation. The prognostic value of FDG-PET/CT has been investigated in the following areas: in the preoperative setting to predict optimal cytoreduction; to assess the value of a positive FDG-PET following primary surgery; and when employed as a replacement for second-look laparotomy following completion of primary surgery and chemotherapy. The data, although promising, are still sparse in all the three domains for a definite recommendation.
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Ovarian cancers are usually detected at advanced stages. They tend to recur despite adequate surgery and chemotherapy. Recurrent ovarian malignancies are difficult to detect and even if detected the prognosis is not very favor able in advanced disease with poor 5year sur vival rates [4] . Despite these factors, detection of early stage disease, early detection of recurrence following completion of therapy and response to therapy are some of the important situations where PET/CT can play an important role for clinical decision making.
With this background, in this review we aim to discuss the impact of PET/CT in the management of ovarian carcinomas.
Basics of FDG-PET/CT imaging in oncology
PET imaging involves the injection of the tracer 18 FFDG, which is a glucose analog [7] . This is followed by imaging in a PET scanner with or without CT. However, most PET scanners today have an integrated CT component, which is useful for attenuation correction as well as anatomical correlation with coregistration. Organs show FDG uptake, which is dependant on the glucose metabolic status of the cells [7] . Glucose uptake is increased manifolds in malig nant cells which forms the basis of increased FDG uptake and functional imaging with FDGPET [7] . 
Nishizawa et al. (2007)
Retrospective analysis of 26 women with serial PET scans and MRI Ovarian FDG uptake is seen even after hysterectomy; needs to be correlated with an anatomical imaging modality (in this study MRI) [9] Zhu et al.
Prospective study of 247 women included in various phases of the menstrual cycle
Ovarian uptake was more prominent in mid-cycle, with the foci of uptake in ovoid shape and located at the left and/or right side superior-posterior to the bladder; patients with irregular cycles have low probability of intense uptake in the ovary [10] Kim et al.
Retrospective analysis of ovarian uptake in 207 women
Increased FDG uptake in the ovary in the peri-ovulatory phase; FDG-PET scan should be planned postmenstrually Data taken from [6] .
PET/CT in physiological conditions of the ovary
In the ovaries, a baseline FDG uptake and a spectrum of cyclical physiological and benign FDG uptake have to be considered in order to detect or diagnose malignant disease. There are known confounding factors of benign/physi ological uptake by the ovaries in the various phases of the menstrual cycle [8] [9] [10] [11] ; these need to be taken care of when PET /CT scans are per formed for the diagnosis of ovarian carcinoma (TaBle 1) . On FDGPET imaging, the ovaries are prominent in the midcycle, with focal uptake located in the left or right side superior and posterior to the urinary bladder. Patients with irregular cycles have a low probability of intense uptake in the ovaries and this should be viewed with high suspicion. Corresponding CT correlation should be done in suspicious cases. Characteristic CT appearance is enhancing cyst and no lymphadenopathy.
It is imperative that FDGPET/CT scan for evaluation of ovarian/pelvic malignancies is performed in the postmenstrual phase in order [18] Kubik-Huch et al.
Prospective 19 Accuracy of PET, CT and MRI for diagnosis (n = 8) and recurrence (n = 11)
No significant difference between all three modalities; poor resolution of PET has a disadvantage; none can replace surgical staging [19] Fenchel et al. High efficiency for differentiating between benign and malignant; but poor for differentiating between borderline malignant and benign [23] Castellucci et al.
50 patients; prospective Efficiency of PET/CT for diagnosis vs TVUS and with CT for staging PET/CT provided incremental value in both diagnosis and staging for ovarian carcinoma [24] Risum et al.
101 patients; prospective
Efficiency of PET/CT for diagnosis of malignancy in pelvic masses PET/CT is the modality of choice for initial diagnosis of suspicious mass on US [25] CT: Computed tomography; TVUS: Transvaginal ultrasound; US: Ultrasound.
to avoid ovarian as well as endometrial activity, which increases in the midcycle and menstrual phases, respectively. In postmenopausal women any ovarian uptake should be viewed with high suspicion.
PET/CT in the diagnosis & initial staging of ovarian cancers
Barring a few reports [12] [13] [14] , it is evident that FDGPET only has no incremental role with regards to initial diagnosis of suspicious pel vic masses (TaBle 2 ) [15] [16] [17] [18] [19] [20] . Transvaginal ultra sound/CT or MRI have been found to be more useful and costeffective modalities in the initial diagnostic evaluation of ovarian malignancies or asymptomatic adnexal masses before the advent of PET/CT. FDGPET did not reveal much incremental benefit over ultrasound, MRI or all three modalities in combination [15, 16] .
The poor resolution of PET was suggested to be a major cause for this impression.
With the advent of FDGPET/CT in recent years, the role of PET imaging is being re explored. PET/CT has been proven to provide incremental information in comparison with CT/MRI only and may play a role in the preop erative staging of carcinoma of the ovary (TaBle 3 ) [21] [22] [23] [24] [25] . This means a better initial staging, which would provide a better outlook for the surgeon before embarking upon primary debulking surgery (Figure 1) .
Overall, PET/CT has a better lesion detec tion rate than CT or MRI alone, better effi ciency to differentiate benign from malignant Factors for prediction of suboptimal cytoreduction were found by PET/CT. LBMI was found to be an independent predictor of incomplete cytoreduction; recommends to use PET/CT only for preoperative evaluation and not for withholding cytoreductive surgery [27] Kurosaki et al.
18 patients; prospective
Followed after primary surgery for mean 2.5 years with PET/CT and CA-125 for prediction of relapse PET/CT positive had a less favorable prognosis than PET/CT negative; but CA-125 was found to be a more useful predictor of prognosis [28] Kim et al. A 45-year-old female patient who was diagnosed with a case of ovary carcinoma with 18 F-fluorodeoxyglucose (FDG)-PET scan performed at initial presentation, demonstrating bulky FDG concentrating lesions in the pelvis with multiple satellite lymph node, regional nodal metastasis and multiple para-aortic lymph node involvement. There is tracer retention within the proximal urinary system of both kidneys. Also noted is intense FDG uptake in the spleen, which is usually observed in the postchemotherapy setting due to extramedullary hematopoiesis related to the effect of colony-stimulating factors [67] . This was unexplained in this case. Figure 2 . 18 F-fluorodeoxyglucose-PET for disease surveillance in patient with a raised level of serum tumor marker. Post-treatment follow-up 18 F-fluorodeoxyglucose (FDG)-PET in a 40-year-old female patient; diagnosed case of carcinoma ovary with abnormally elevated serum CA-125 (535 U/ml). Whole-body FDG-PET demonstrating abnormal foci, suggesting active disease in the para-aortic and pelvic group of lymph nodes on the right side. Initial scan had urinary tracer collection interfering with the disease foci, which were well delineated on the postfurosemide regional PET study. lesions -except for borderline lesions -and to pick up other unexpected tumors. Thus, the incremental value of PET/CT has been well proven in initial staging workup although surgery still remains the gold standard.
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PET/CT in disease prognostication
PET/CT has been found to be of some incre mental value in prognostication and predic tion of disease [26] [27] [28] [29] [30] [31] [32] after primary treatment, although it does not stand a very strong hold in this area (TaBle 4) [27, 28, 31] . Risum et al. demon strated that factors for predicting suboptimal cytoreduction include large bowel mesenteric deposits, which could be picked up on PET/CT with high sensitivity prior to surgery and thus help in prognostication [27] . However, the few studies done in this area cannot be very strong contenders to replace secondlook laparotomy [31, 32] . Presently, Phase III randomized trials are still ongoing to examine if the information generated based on the results of PET/CT will be useful in predicting and selecting a specific management plan in this scenario [26] . The pri mary aim here would be to see if PET/CT could replace secondlook laparotomy. There is still not enough data to conclude that this is so.
PET/CT in detecting disease recurrence of ovarian carcinoma
The highest impact of PET/CT in ovarian can cers is in the detection of recurrence as this is one of the most common malignancies to recur despite adequate therapy (Figures 2 & 3) . There are extensive data in this area (TaBle 5) [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Various studies [33, 34] have revealed the signifi cant alteration in the management of patients (>50%) with suspected disease recurrence by the introduction of PET/CT. PET/CT reveals lesions in nodal, peritoneal and subcapsular liver disease with higher sensitivity and accuracy, which are otherwise challenging to interprete with CT alone [41] . Only one study favored MRI and has shown a better sensitivity and accuracy of MRI in comparison with PET/CT, but the details of the study (e.g., selection of patients, interpretation skills and sample size) need to be considered in larger multicentric trials [39] . It should be observed that in this area PET alone as well as PET/CT have both been reported to perform well [42] .
In fact, this is one definitive clinical indica tion that has been shown to be costeffective as well. The use of PET/CT in the group of patients with suspected recurrent disease is costeffective and can be allowed to redirect the 18 F-fluorodeoxyglucose-PET documenting disease recurrence after a prolonged complete remission. A 52-year-old female who previously had a case of breast carcinoma but was post-treatment and had been in complete remission for 10 years, developed carcinoma of both the ovaries. The patient underwent total abdominal hysterectomy and bilateral salphingo-oophorectomy with chemotherapy. Follow-up assessment 4 years post-treatment revealed abnormally elevated CA-125 (105 U/ml). Whole-body 18 F-fluorodeoxyglucose-PET scan demonstrating focal abnormal tracer concentration within the right lobe of the liver. Also noted is prominent blood pool activity in the heart and major vessels including the upper limb vessels, which is at times observed incidentally. use, but surgical planning is helpful to select resectable areas [37] Gu et al.
Review PET alone, PET/CT CA-125, CT and MRI in diagnosis of recurrent ovarian cancer PET/CT useful in detection of recurrence; CT component shown to have limited additional value [38] Kim et al.
36 patients; prospective Comparison of PET/CT with MRI for detection of recurrence MRI (86%) found to be more sensitive than PET/CT (66%) [39] Sheng et al.
(2007) 26 patients; prospective Performance of PET/CT for early detection of recurrence, in rising CA-125 levels High accuracy of PET/CT for detection of recurrence in combination with CA-125 levels; also increases accuracy of recytoreductive surgery [40] Sebastian et al.
51 patients; prospective PET/CT vs CT alone for recurrence PET/CT demonstrates greater accuracy and less interobserver variability than CT alone [41] GarciaVelloso et al.
86 patients; retrospective PET for detection of recurrence compared with conventional radiological imaging PET can detect recurrence earlier with more sensitivity and accuracy than conventional radiological imaging [42] Thrall et al.
39 patients; retrospective PET/CT for detection of recurrence PET/CT high detection of recurrence especially in rising CA-125 and negative conventional imaging [43] Mangili et al.
32 patients; retrospective PET/CT vs CT for suspected recurrence PET/CT detected more recurrences and altered management in 44% of patients [44] Chung et al. prospective PET, CT and PET/CT compared for recurrence PET/CT detects more lesions than PET or CT alone [47] Bristow et al.
(2005) 14 patients; retrospective PET/CT showed high sensitivity and positive predictive value in identifying recurrent ovarian cancer among patients with rising CA-125 levels and negative or equivocal conventional imaging (e.g., CT) findings PET/CT has a high positive predictive value in this region known for occult recurrence [48] Nanni et al.
41 patients; prospective PET/CT done after primary treatment; for recurrence in addition to CA-125, CT/MRI/USG PET/CT showed a good sensitivity (88.2%), specificity (71.4%) and accuracy (85.4%), for detection of recurrence (early study) [49] Bristow et al. clinical management of patients towards more appropriate therapeutic choices [51] .
PET/CT in peritoneal metastases
In patients with metastatic ovarian carcinoma, disease sensitivity of both 18 FFDGPET and CT for the detection of peritoneal metastases is low; however, with regards to better specificity of FDGPET, it is preferred for evaluation of residual/recurrent disease with better sensitivity for the retroperitoneal region than the intra peritoneal region (Figure 4a & B) . Surgical staging remains the gold standard [52] .
Performance of PET has been found to be a useful tool for the detection of the peritoneal deposits [53] [54] [55] [56] . This is due to two factors, in particular: detection of peritoneal carcinomato sis is difficult with CT due to poor sensitivity. Detection with peritoneal biopsy is also fraught with high incidence of sampling errors. Two dis tinct abnormal scintigraphic patterns of focal and uniform 18 FFDG uptake corresponding to nodular and diffuse peritoneal disease on pathologic examination have been observed for peritoneal carcinomatosis on FDGPET [57] .
PET in assessing response to therapy
FDGPET uptake in the tumor prior to therapy and after neoadjuvant chemotherapy or chemo radiotherapy in advanced ovarian cancers has been studied [58, 59] . Standardized uptake value (SUV)based assessment of response has been found to be accurate; however, the role of PET in the context of patient management and the cost-effectiveness of this approach needs fur ther evaluation [59, 60] . Therapy monitoring by PET could help to optimize neoadjuvant therapy protocols and to avoid ineffective preoperative therapy in nonresponders, but this has to be proven in a larger number of patients and in different neoadjuvant settings such as chemotherapy, radiation therapy, hor mone therapy or a combination of these [61] . The results of PET/CT in this situation could also translate into prognostication of the dis ease. There is relatively less defined course in terms of therapeutic intervention with positive PET/CT results in this clinical setting when compared with other malignancies. This is one of the main reasons why PET/CT is not yet popular in this area [60] .
Figure 4. 18 F-fluorodeoxyglucose-PET imaging of ovarian carcinoma demonstrating different sites of disease involvement including the peritoneum. (A)
A 50-year-old female patient with a diagnosed case of carcinoma of the ovary. 18 F-fluorodeoxyglucose (FDG)-PET study demonstrating extensive 18 F-FDG concentrating lesions of varying size and intensity involving the liver, the peritoneum, lymphatic and extra-lymphatic soft tissue in the abdomen and pelvis. (B) A 40-yearold female patient diagnosed with a case of carcinoma of the ovary post-treatment assessment with whole-body 18 F-FDG-PET, demonstrating extensive residual 18 F-FDG-concentrating large lesions in the epigastric region, multiple focal hepatic lesions of varying size and intensity, multiple peritoneal deposits and a few small lesions with necrotic areas in the pelvis on the right side.
PET in metastatic ovarian cancer & in the setting of rising CA-125 levels
Ovarian cancer can spread locally within the pelvis with subsequent spread within the peritoneal cav ity to the rest of the abdomen. Tumor spread can also occur via lymphatics and hematogenously. Lymphadenopathy can be seen in the inguinal, pelvic and paraaortic regions. Hematogenous sites of spread include the liver and lung [62] .
Distant metastasis is also seen in the liver, pleura, mediastinum and supraclavicular lymph nodes ( Figure 5 ) [24] . Kim et al. broadly classified recurrent ovarian tumors in the abdomen and pelvis based on site as follows: local pelvic recur rence; peritoneal lesion; lymph nodal metasta sis; and distant metastasis [39] . PET/CT showed an excellent sensitivity and specificity of nearly 100% for detection for all sites of metastasis viz local spread, peritoneal lesions, inguinal and pelvic lymph nodes and distant metastasis in liver and lungs, except for the paraaortic lymph nodes where PET performance was observed to be relatively low [37] . Overall, PET/CT has been found to have better sensitivity than CT alone for the detection of distant metastasis [24, 62] .
Although we have discussed the role of PET/CT in detecting recurrent/metastatic disease, the area of rising CA125 levels (tumor markers) with normal anatomical imaging (CT/MRI) deserves special mention (Figure 6) . CT has been shown to have quite a low nega tive predictive value for recurrence suspected owing to rising CA125 levels [37] . Makhija et al. reported that PET/CT could identify recurrent disease in 62% of patients with nega tive CT scans [63] . Soussan et al. have shown that PET/CT imaging allows for better restag ing than CT and induces a change in clinical management in over a third of patients with suspected ovarian carcinoma recurrence with increased CA125 [64] .
Overall, better lesion detection in rising tumor markers has been seen with PET/CT than with CT alone [35, 40] .
Other issues: differentiation of benign versus malignant lesions in ovarian tumor imaging
This is an extension of the initial point discussed under the section, 'PET/CT in the diagnosis & initial staging of ovarian cancers.' Hypermetabolic ovarian lesions, more intense than the physiologi cal hepatic uptake have been considered positive for malignancy in most studies, although in our experience significant overlap can be observed in practice. A cutoff value of SUV greater than or equal to three has been seen to be highly sug gestive of malignancy in some studies [62] . SUVs ranging from 3 to 27 have been seen in malignant lesions proven by histopathology [65] . The SUV cutoffbased diagnosis, however, would require more validation. Lesions within SUV of less than two have been considered to be benign by some authorities even if other imaging modali ties are positive, for example in borderline ovar ian tumors [66] . We believe that more data with PET/CT imaging needs to be accrued in this area for a definitive conclusion.
Conclusion
Theoretically, fusing functional and anatomi cal information can be of significant benefit for the detection of abdominal lesions such as that in ovarian cancer. Hence, this modality needs to be utilized to its greatest potential in this malignancy. At present, PET/CT does not play a significant additional role in the primary diagnosis of ovarian cancers and holds a posi tion similar to transvaginal ultrasound/CT for this purpose. Primary staging of diagnosed pri mary ovarian tumors can be better staged using PET/CT before any form of treatment as it adds valuable information regarding the number and extent of lesions. The monitoring of therapy response with PET/CT has cost-effectiveness issues, which need further evaluation. The most definite role of PET/CT is in the surveillance of patients who have received primary therapy with rising CA125 levels or even normal CA125 lev els with high clinical suspicion. It does perform relatively poorly in peritoneal carcinomatosis, but the overall performance is better than CT alone. PET/CT can pick up unsuspected lesions whether nodal, in the peritoneum or subcapsular liver disease.
Future perspective
The wide application of current generation PET/CT scanners with better resolution in rou tine clinics will likely increase the role and reli ability of this imaging modality in this group of tumors. We speculate the areas in which PET/CT may develop a role in the clinical manage ment of ovarian carcinoma in the future are: as a promising technique in monitoring response to therapy; initial staging of the disease (particu larly the metastatic disease burden) with better accuracy that would guide the correct therapeu tic strategy; and disease prognostification espe cially as a replacement of secondlook laparotomy following completion of primary therapy.
In these areas, presently this is not used in routine clinics but might change with better results with the application of combined struc turefunction approach and better quantification techniques. This would, however, be determined by results from more clinical studies, evidence based approach and the availability of newer salvage treatment modalities. 18 F-fluorodeoxyglucose (FDG) uptake in the right hilum, corresponding to a 1.6 cm in size lymph node on CT, consistent with metastasis; transaxial PET/CT slice through the focus of 18 F-FDG uptake in the right lower quadrant (B) demonstrates moderate 18 F-FDG uptake in the 0.5-cm right serosal implant, consistent with metastasis. This lesion was identified on CT retrospectively because of 18 F-FDG uptake. (C-D) 3 months post chemotherapy, transaxial PET/CT slice through the chest (C) demonstrates more intense (greater than blood pool) 18 F-FDG uptake in the right hilar lymph node and a slight increase in size, consistent with progressive disease; transaxial PET/CT slice through the pelvis (D) demonstrates more intense 18 F-FDG uptake in the right serosal implant, consistent with progressive disease. Reproduced with permission from [68] . 
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Executive summary
Background
• Ovarian cancers being the sixth most common cancer among women with notoriety to being detected at advanced stages and to recur despite adequate treatment, makes them a challenging disease.
• Evaluation with primary staging (according to the International Federation of Obstetricians and Gynecologists), followed by chemotherapy and surgery is the usual course of management of these malignancies.
PET/computed tomography in physiological conditions of the ovary • Ovaries show physiologically increased uptake of 18 F-fluorodeoxyglucose (FDG) in midcycle of menstruation, which does not happen in patients with irregular cycles or postmenopausal women and thus should be reviewed with suspicion in such patients.
• It is thus imperative to image these malignancies in the postmenstrual phase.
PET/computed tomography in initial disease staging • The transvaginal ultrasound and computed tomography (CT)/MRI have been the most popular modalities for diagnosis of the primary and initial staging in contrast to FDG-PET only.
• With the advent of FDG-PET/CT, it is being observed that fusion imaging does provide incremental information in contrast to only anatomical imaging for initial disease staging as a whole-body modality (especially with regard to metastatic disease burden).
• PET/CT has better lesion detection rates and better differentiation of benign from malignant and the probability to pick up unexpected tumors.
PET/CT in disease prognostication
• Primary aim is to see if PET/CT could replace second-look laparotomy for which Phase III randomized trials are ongoing and results require evaluation.
FDG-PET & PET/CT in the setting of rising CA-125 levels (detection of disease recurrence/metastatic disease)
• Ovarian cancers could spread or recur locally within the pelvis whereas metastatic involvement includes peritoneal cavity spread, lymphatic spread to inguinal, pelvic and para-aortic nodes or hematogenous spread to liver and lungs.
• PET/CT shows highest impact in this area where it demonstrates higher sensitivity and accuracy in detecting disease involvement in areas like nodal, peritoneal and subcapsular liver disease, which are challenging otherwise with conventional imaging. The assessment of whole-body status is a distinct advantage of this modality in the detection of distant metastasis.
• Rising CA-125 with normal anatomical imaging thus forms a definitive indication for FDG-PET/CT imaging. The application results in change in clinical management of over a third of such patients.
PET/CT in peritoneal metastasis
• Though both PET and CT perform low in this area, PET-CT has been found to be more useful than CT alone and, hence, should be preferred compared with anatomical imaging alone.
• FDG-PET/CT shows two distinct patterns of uptake (i.e., focal and uniform uptake for nodular and diffuse peritoneal disease, respectively).
PET in assessing response to therapy
• Standardized uptake value based response monitoring has been found to be accurate early in the course of therapy; however, there are cost-effectiveness issues in this area.
Differentiation of benign versus malignant ovarian lesions
• Always a challenge in FDG-PET imaging; validation with more studies needs to be continued. Standardized uptake values have been used in most studies and a value of three or more have been suggested to be highly suggestive of malignancy; however, this requires to be critically determined. Combined PET-CT and dual time point imaging may help.
